Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of a recurrent primary brain tumor with no curative therapy available.~* Measurable disease using pediatric Response Assessment in Neuro-Oncology Criteria (RANO) criteria.~* Life expectancy \> 12 weeks~* Prior treatment with radiation alone, chemotherapy alone or combined radiation and chemotherapy is allowed.~* Patient is \< 21 years of age~* Normal bone marrow and organ function as defined below:~  * Leukocytes ≥ 3,000/mcL~ * Absolute neutrophil count ≥ 1,500/mcl~ * Platelets ≥ 100,000/mcl~ * Total bilirubin ≤ 1.5 x IULN~ * AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN~ * Creatinine ≤ IULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal~ * Normal room air oxygenation must be documented. If room air oxygen saturation is less than 97%, a diffusion capacity of carbon monoxide (DLCO) of greater than 80%, must be demonstrated.~* Karnofsky or Lansky performance score of ≥ 60~* Patients of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.~* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).~Exclusion Criteria:~* Patient does not have any of the following conditions as they are contraindicated for ketogenic diet:~  * Primary and secondary carnitine deficiency~ * Carnitine palmitoyltransferase I or II deficiency~ * Carnitine translocase deficiency~ * Mitochondrial β-oxidation defects~ * Pyruvate carboxylase deficiency~ * Glycogen storage diseases~ * Ketolysis defects~ * Ketogenesis defects~ * Porphyria~ * Prolonged QT syndrome~ * Liver insufficiency~ * Renal insufficiency~ * Pancreatic insufficiency~ * Pulmonary insufficiency~ * Hyper insulinism~* Pregnant and/or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test within 14 days of study entry.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Ketogenic Diet (Type: EXPERIMENTAL): * Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~* Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~* Laboratory studies prior to hospital admission and then at each follow-up visit~* Hospital admission (3-5 day) to start the ketogenic diet~* Standard of care chemotherapy with BCNU for up to 2 years~* Ketogenic diet can continue for up to 2 years

Based on this trial design, predict the completion outcome and termination type (if applicable).